HIGHLIGHTS
- who: Ming Zheng from the des Cordeliers (CRC), France University, China have published the research: Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications, in the Journal: (JOURNAL)
- how: The authors presented the data modeling the TMB gradient as a continuous risk predictor of the OS following ICB treatment.
SUMMARY
Over the past decade, immunotherapy has revolutionized cancer treatment by inducing durable remission and prolonging patient survival in diverse types of cancer. In the landscape of cancer immunotherapies, therapeutically targeting immune inhibitory checkpoints through . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.